NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the therapy of palmar hyperhidrosis utilizing its patented microchannel know-how™. DTX-024 is a extremely purified and clinically examined injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum.

Aquavit Emblem (PRNewsfoto/Aquavit Prescribed drugs, Inc.)

Alongside Aquavit’s biosimilar program for its botulinum toxin, this would be the first on the planet, indicated for palmar hyperhidrosis, permitted by FDA.

Aquavit has been investing in proprietary supply applied sciences and associated mental property for botulinum toxin. It is a strategic transfer that places them forward of the curve within the fast-growing multi-billion-dollar botulinum toxin market.

To successfully execute the technique, Aquavit has just lately bolstered its government staff with seasoned veterans from the business and the academia.

Dr. David Crean, PhD, MBA has been named Chief Monetary Officer of Aquavit Holdings. He has buy- and sell-side experience in mergers & acquisitions (M&A), partnering and investments throughout the life sciences and healthcare sectors working inside strategic biopharmaceutical firms, non-public fairness, funding banking and enterprise capital. He commenced his profession inside biopharmaceutical firms greater than 30 years in the past, most notably at Allergan, an Abbvie Firm, the place he lead deal execution for each know-how, product, and firm acquisitions and divestitures throughout a broad vary of therapeutic areas and enterprise items together with injectable and topical medical aesthetics, dermatology, neurology, and ophthalmology. He serves on a number of boards together with each private and non-private firms and has been awarded quite a few recognitions together with San Diego’s 500 Most Influential individuals for the previous 4 years (2019 -2022), 2020 Prime Thought Leaders by Axial, M&A Advisor of the Yr in 2019, and the 2018 Healthcare Hero Award.

Dr. Crean holds FINRA Sequence 79 and Sequence 63 licenses and is a Registered Funding Banking Consultant of BA Securities LLC, Member FINRA SIPC.

Story continues

Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Medical Officer. He’s a skilled neurosurgeon and neuroscientist who brings a wealth of expertise and data to scientific developments, drug improvement and approval, and new drug discovery. He holds his levels from College of Oxford and Harvard Medical College and presently holds a tutorial place at Columbia Medical College.

With Aquavit’s confirmed observe document of growing and launching world manufacturers, similar to AQUAGOLD®, the corporate has demonstrated their potential to efficiently carry modern merchandise to market. With their deep data of botulinum toxin and intensive community of physicians, Aquavit is well-positioned to make a major affect within the business.

“The neurotoxin market is increasing quickly, with rising demand for modern merchandise and personalised therapy plans. There’s presently no FDA approval for palmar hyperhidrosis and thru our novel route of administration we will provide new options to satisfy the evolving wants of sufferers in pathologies which can be extraordinarily debilitating. The availability of entry for this inhabitants is a step in the precise path in the direction of enhancing their well being and well-being. ” Churl-Su Kwon, CMO Aquavit.

About Aquavit
Aquavit is an modern healthcare firm that gives a complete vary of proprietary pharmaceutical, biotech and medical machine applied sciences. Aquavit focuses on personalised medication to enhance sufferers’ well being, maximize the effectivity of our medical neighborhood, and help the pharmacoeconomics of payers.

Cision

View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/aquavit-files-additional-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technology-for-palmar-hyperhidrosis-301775589.html

SOURCE Aquavit Holdings